KRAS is the most common driver oncogene in CRC and many other tumors, based in large part on its ability to simultaneously activate BRAF, PI3K, and other signaling effectors, which collaborate to induce tumor proliferation, survival, and other processes associated with progression30. Here, PIK3CA is linked to colorectal carcinoma.